|
1. Furuichi, Y., A. LaFiandra, and A.J. Shatkin, 5′-Terminal structure and mRNA stability. Nature, 1977. 266(5599): p. 235-239. 2. Darnell Jr, J.E., Transcription units for mRNA production in eukaryotic cells and their DNA viruses. Progress in nucleic acid research and molecular biology, 1979. 22: p. 327-353. 3. Dominissini, D. and G. Rechavi, 5-methylcytosine mediates nuclear export of mRNA. Cell research, 2017. 27(6): p. 717-719. 4. Filipowicz, W., et al., A protein binding the methylated 5'-terminal sequence, m7GpppN, of eukaryotic messenger RNA. Proceedings of the National Academy of Sciences, 1976. 73(5): p. 1559-1563. 5. Frye, M. and S. Blanco, Post-transcriptional modifications in development and stem cells. Development, 2016. 143(21): p. 3871-3881. 6. Furuichi, Y., Discovery of m7G-cap in eukaryotic mRNAs. Proceedings of the Japan Academy, Series B, 2015. 91(8): p. 394-409. 7. Leung, D.W. and G.K. Amarasinghe, When your cap matters: structural insights into self vs non-self recognition of 5′ RNA by immunomodulatory host proteins. Current opinion in structural biology, 2016. 36: p. 133-141. 8. Zhao, J., L. Hyman, and C. Moore, Formation of mRNA 3′ ends in eukaryotes: mechanism, regulation, and interrelationships with other steps in mRNA synthesis. Microbiology and molecular biology reviews, 1999. 63(2): p. 405-445. 9. Fechter, P. and G.G. Brownlee, Recognition of mRNA cap structures by viral and cellular proteins. Journal of General Virology, 2005. 86(5): p. 1239-1249. 10. Shatkin, A., Capping of eucaryotic mRNAs. Cell, 1976. 9(4): p. 645-653. 11. Wei, C.-M., A. Gershowitz, and B. Moss, N6, O2′-dimethyladenosine a novel methylated ribonucleoside next to the 5′ terminal of animal cell and virus mRNAs. Nature, 1975. 257(5523): p. 251-253. 12. Bienroth, S., W. Keller, and E. Wahle, Assembly of a processive messenger RNA polyadenylation complex. The EMBO journal, 1993. 12(2): p. 585-594. 13. Balbo, P.B. and A. Bohm, Mechanism of poly (A) polymerase: structure of the enzyme-MgATP-RNA ternary complex and kinetic analysis. Structure, 2007. 15(9): p. 1117-1131. 14. Pardi, N., et al., mRNA vaccines—a new era in vaccinology. Nature reviews Drug discovery, 2018. 17(4): p. 261-279. 15. Rosa, S.S., et al., mRNA vaccines manufacturing: Challenges and bottlenecks. Vaccine, 2021. 39(16): p. 2190-2200. 16. Bustin, S.A., Absolute quantification of mRNA using real-time reverse transcription polymerase chain reaction assays. Journal of molecular endocrinology, 2000. 25(2): p. 169-193. 17. Mora, J.R. and R.C. Getts, High-sensitivity detection methods for low-abundance RNA species: applications for functional genomics research. Expert review of molecular diagnostics, 2007. 7(6): p. 775-785. 18. Carrascosa, L.G., C.S. Huertas, and L.M. Lechuga, Prospects of optical biosensors for emerging label-free RNA analysis. Trac Trends in Analytical Chemistry, 2016. 80: p. 177-189. 19. Vlatkovic, I., et al., Ribozyme Assays to Quantify the Capping Efficiency of In Vitro-Transcribed mRNA. Pharmaceutics, 2022. 14(2): p. 328. 20. Beverly, M., et al., Label-free analysis of mRNA capping efficiency using RNase H probes and LC-MS. Analytical and bioanalytical chemistry, 2016. 408(18): p. 5021-5030. 21. Russo, J., et al., Engineered viral RNA decay intermediates to assess XRN1-mediated decay. Methods, 2019. 155: p. 116-123. 22. Efimov, V., et al., Detection of the 5′-cap structure of messenger RNAs with the use of the cap-jumping approach. Nucleic acids research, 2001. 29(22): p. 4751-4759. 23. Fuchs, A.-L., A. Neu, and R. Sprangers, A general method for rapid and cost-efficient large-scale production of 5′ capped RNA. RNA, 2016. 22(9): p. 1454-1466. 24. Moya-Ramírez, I., et al., High resolution biosensor to test the capping level and integrity of mRNAs. Nucleic acids research, 2020. 48(22): p. e129-e129. 25. Grifo, J., et al., New initiation factor activity required for globin mRNA translation. Journal of Biological Chemistry, 1983. 258(9): p. 5804-5810. 26. Sonenberg, N., et al., Eukaryotic mRNA cap binding protein: purification by affinity chromatography on sepharose-coupled m7GDP. Proceedings of the National Academy of Sciences, 1979. 76(9): p. 4345-4349. 27. Sonenberg, N., et al., A polypeptide in eukaryotic initiation factors that crosslinks specifically to the 5'-terminal cap in mRNA. Proceedings of the National Academy of Sciences, 1978. 75(10): p. 4843-4847. 28. Marcotrigiano, J., et al., Cocrystal structure of the messenger RNA 5′ cap-binding protein (eIF4E) bound to 7-methyl-GDP. Cell, 1997. 89(6): p. 951-961. 29. Rogers Jr, G.W., A.A. Komar, and W.C. Merrick, eIF4A: the godfather of the DEAD box helicases. 2002. 30. Schütz, P., et al., Crystal structure of the yeast eIF4A-eIF4G complex: An RNA-helicase controlled by protein–protein interactions. Proceedings of the National Academy of Sciences, 2008. 105(28): p. 9564-9569. 31. Amorim, I.S., G. Lach, and C.G. Gkogkas, The role of the eukaryotic translation initiation factor 4E (eIF4E) in neuropsychiatric disorders. Frontiers in genetics, 2018. 9: p. 561. 32. Siddiqui, N. and N. Sonenberg, Signalling to eIF4E in cancer. Biochemical Society Transactions, 2015. 43(5): p. 763-772. 33. Mamane, Y., et al., eIF4E–from translation to transformation. Oncogene, 2004. 23(18): p. 3172-3179. 34. Furic, L., et al., eIF4E phosphorylation promotes tumorigenesis and is associated with prostate cancer progression. Proceedings of the National Academy of Sciences, 2010. 107(32): p. 14134-14139. 35. Dong, Q., et al., Tumor-derived exosomal eIF4E as a biomarker for survival prediction in patients with non-small cell lung cancer. Medical Science Monitor: International Medical Journal of Experimental and Clinical Research, 2020. 26: p. e923210-1. 36. Choi, Y.H. and C.H. Hagedorn, Purifying mRNAs with a high-affinity eIF4E mutant identifies the short 3′ poly (A) end phenotype. Proceedings of the National Academy of Sciences, 2003. 100(12): p. 7033-7038. 37. Rahman, M. and M.M. Karim, Heterologous Expression of a Human Cap-Binding Protein eIF4E in Escherichia coli. Dhaka University Journal of Pharmaceutical Sciences, 2006. 5(1): p. 59-62. 38. Thaller, M.C., et al., Identification of the gene (aphA) encoding the class B acid phosphatase/phosphotransferase of Escherichia coli MG1655 and characterization of its product. FEMS Microbiology Letters, 1997. 146(2): p. 191-198. 39. Terpe, K., Overview of tag protein fusions: from molecular and biochemical fundamentals to commercial systems. Applied microbiology and biotechnology, 2003. 60(5): p. 523-533. 40. Schmidt, S.R., Fusion-proteins as biopharmaceuticals–applications and challenges. Curr Opin Drug Discov Devel, 2009. 12(2): p. 284-295. 41. Kim, B.-J., et al., Transferrin fusion technology: a novel approach to prolonging biological half-life of insulinotropic peptides. Journal of Pharmacology and Experimental Therapeutics, 2010. 334(3): p. 682-692. 42. Zhao, H.L., et al., Increasing the homogeneity, stability and activity of human serum albumin and interferon-α2b fusion protein by linker engineering. Protein expression and purification, 2008. 61(1): p. 73-77. 43. Amet, N., H.-F. Lee, and W.-C. Shen, Insertion of the designed helical linker led to increased expression of tf-based fusion proteins. Pharmaceutical research, 2009. 26(3): p. 523-528. 44. Bai, Y. and W.-C. Shen, Improving the oral efficacy of recombinant granulocyte colony-stimulating factor and transferrin fusion protein by spacer optimization. Pharmaceutical research, 2006. 23(9): p. 2116-2121. 45. Waldo, G.S., et al., Rapid protein-folding assay using green fluorescent protein. Nature biotechnology, 1999. 17(7): p. 691-695. 46. Maeda, Y., et al., Engineering of functional chimeric protein G–VargulaLuciferase. Analytical biochemistry, 1997. 249(2): p. 147-152. 47. Chen, X., et al., Design of an in vivo cleavable disulfide linker in recombinant fusion proteins. Biotechniques, 2010. 49(1): p. 513-518. 48. Wu, J., et al., Ribogenomics: the science and knowledge of RNA. Genomics, proteomics & bioinformatics, 2014. 12(2): p. 57-63. 49. Carino, E.J., K. Scheets, and W.A. Miller, The RNA of maize chlorotic mottle virus, an obligatory component of maize lethal necrosis disease, is translated via a variant panicum mosaic virus-like cap-independent translation element. Journal of virology, 2020. 94(22): p. e01005-20. 50. Hellman, L.M. and M.G. Fried, Electrophoretic mobility shift assay (EMSA) for detecting protein–nucleic acid interactions. Nature protocols, 2007. 2(8): p. 1849-1861. 51. Von der Haar, T., P.D. Ball, and J.E. McCarthy, Stabilization of eukaryotic initiation factor 4E binding to the mRNA 5′-Cap by domains of eIF4G. Journal of Biological Chemistry, 2000. 275(39): p. 30551-30555. 52. Maria, C.T., et al., Cloning and characterization of the NapA acid phosphatase/phosphotransferase of Morganella morganii: identification of a new family of bacterial acid-phosphatase-encoding genes. Microbiology, 1995. 141(1): p. 147-154. 53. Uerkvitz, W., Periplasmic nonspecific acid phosphatase II from Salmonella typhimurium LT2. Crystallization, detergent reactivation, and phosphotransferase activity. Journal of Biological Chemistry, 1988. 263(30): p. 15823-15830. 54. Goss, D.J. and F.E. Kleiman, Poly (A) binding proteins: are they all created equal? Wiley Interdisciplinary Reviews: RNA, 2013. 4(2): p. 167-179.
|